Hematology/Oncology

Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.

May 12, 2020

CCNE1 amplification is a recurrent alteration associated with unfavourable outcome in tubo-ovarian...

Strategic combination therapies for ovarian cancer.

May 12, 2020

Ovarian cancer remains the leading cause of gynecologic cancer-related death among women...

AACR 2020: Pre-existing ESR1 Mutations Predict Endocrine Therapy Failure & Poor Survival

May 1, 2020

Despite research suggesting that mutation in ESR1 is an acquired mechanism of resistance to...

Conference Highlights: AACR 2020

May 1, 2020

New research was virtually presented at AACR 2020, the American Association for Cancer Research...

Pregnancy-related risk factors for sex cord-stromal tumours and germ cell tumours in parous women: a registry-based study.

Apr 28, 2020

Non-epithelial ovarian cancers are divided into sex cord-stromal tumours (SCSTs) and germ cell...

Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199).

Apr 28, 2020

Risk-reducing salpingo-oophorectomy (RRSO) has been associated with approximately 50% breast...

The first copper(ii) complex with 1,10-phenanthroline and salubrinal with interesting biochemical properties.

Apr 28, 2020

The novel copper complex [Cu(phen)2(salubrinal)](ClO4)2 (C0SAL) has been synthesised and...

The generally low sensitivity of CA 125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype.

Apr 28, 2020

The serum marker CA 125 is still the most widely used biomarker for ovarian cancer (OC) diagnosis...

Filopodia play an important role in the trans-mesothelial migration of ovarian cancer cells.

Apr 28, 2020

Ovarian cancer cells shed from primary tumors can spread easily to the peritoneum via the...

Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C.

Apr 22, 2020

A central and unique aspect of high-grade serous ovarian carcinoma (HGSC) is the extensive...

Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer.

Apr 22, 2020

Collagen type XI alpha 1 (COL11A1) is a novel biomarker associated with cisplatin resistance in...

Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancer.

Apr 22, 2020

The Wnt/β-catenin pathway is linked to tumorigenesis in a variety of tumors and promotes T cell...

Population Screening for Inherited Predisposition to Breast and Ovarian Cancer.

Apr 22, 2020

The discovery of genes underlying inherited predisposition to breast and ovarian cancer has...

Design of Fluorophore Loaded Human Serum Albumin Nanoparticles for Specific Targeting of NIH:OVCAR3 Ovarian Cancer Cells.

Apr 22, 2020

Nowadays, extensive research is carried out into finding innovative solutions for the development...

Mitomycin Gel Gets FDA Nod for Low-Grade Upper Tract Urothelial Tumors

Apr 16, 2020

The first non-surgical treatment option for a rare cancer subtype WASHINGTON — Mitomycin gel (Jelmyto), an alkylating drug, is now FDA-approved as the first non-surgical treatment for low-grade upper tract urothelial...

SGO: ProMisE-ing Predictions for Progression in Endometrial Ca

Apr 16, 2020

Algorithm helps identify which patients can be offered fertility-sparing treatment options Using the Proactive Molecular Classifier for endometrial cancer (ProMisE) algorithm to classify patients with endometrial cancer or...

Mitomycin Gel Gets FDA Nod for Low-Grade Upper Tract Urothelial Tumors

Apr 16, 2020

The first non-surgical treatment option for a rare cancer subtype WASHINGTON — Mitomycin gel (Jelmyto), an alkylating drug, is now FDA-approved as the first non-surgical treatment for low-grade upper tract urothelial...